Showing 6031-6040 of 7771 results for "".
- Phase 1 Study Begins for New Systemic for CPUOhttps://practicaldermatology.com/news/Phase-1-Study-Begins-New-Systemic-CPUO/2471095/The first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE) anti-IL-31 biotherapeutic, Attovia Therapeutics announced. ATTO-1310 is being evaluated as a potential systemic treatment for people living with pruritic co
- Study: Quality, Reliability of TikTok Videos on Spironolactone Is Suspecthttps://practicaldermatology.com/news/Study-Quality-Reliability-TikTok-Videos-Spironolactone-Suspect/2471094/The quality and reliability of information on TikTok regarding spironolactone for acne treatment is concerning, according to a new study by George Washington University researchers. An analysis of the top 50 TikTok videos under the hashtag #spironolactone, which had received 108 million vi
- GW Earns Skin Smart Campus Recognitionhttps://practicaldermatology.com/news/GW-Earns-Skin-Smart-Campus-Recognition/2471093/The National Council on Skin Cancer Prevention recognized George Washington University as a Skin Smart Campus for its ongoing commitment to fostering a safe and healthy learning environment, with a focus on skin cancer prevention and UV safety, the university announced. The Skin Smart Camp
- Higher Complication Rates in Large Skin Reconstructions: Studyhttps://practicaldermatology.com/news/higher-complication-rates-in-large-skin-reconstructions-study/2471062/Large cutaneous reconstructions performed under local anesthesia (including complex linear closures [CLCs], flaps, and grafts) are generally safe but have higher complication rates compared to smaller procedures, a recent study from the University of California, San Diego showed. The retro
- Study: Newer Biologics Do Not Increase MACE/VTE Risk in PsO/PsAhttps://practicaldermatology.com/news/Study-Newer-Biologics-Do-Not-Increase-MACE-VTE-Risk-PsO-PsA/2471065/A new emulated target trial analysis found no significant risk differences in major adverse cardiovascular events (MACE) or venous thromboembolic events (VTE) in patients with psoriasis or psoriatic arthritis treated with IL-17, IL-12/23, or IL-23 inhibitors vs those treated with TNF inhibitors.<
- Study Shows Oral Minoxidil Improves Patient Outcomes for Hair Losshttps://practicaldermatology.com/news/study-shows-oral-minoxidil-improves-patient-outcomes-for-hair-loss/2471041/New research in the Journal of Drugs in Dermatology shows oral minoxidil outperforming topical formulations in terms of patient adherence, satisfaction, and ease of use, without significantly increasing systemic side effects. Researchers on the study studied 50 patients using eith
- Biologic Therapy in Psoriasis: Secukinumab and Ustekinumab Lead in Retentionhttps://practicaldermatology.com/news/biologic-therapy-in-psoriasis-secukinumab-and-ustekinumab-lead-in-retention/2471042/Switching patterns of biologics in psoriasis treatment revealed influences of gender and psoriatic arthritis (PsA), according to new research. The retrospective study from the nationwide digital prescription database of Greece has shed light on biologic treatment trends for psoriasis betwe
- Cosmetic Laser Market to Reach $14.79 Billion by 2033: Reporthttps://practicaldermatology.com/news/cosmetic-laser-market-to-reach-1479-billion-by-2033-report/2471023/The global cosmetic lasers market is projected to grow to $14.79 billion by 2033, at a compound annual growth rate (CAGR) of 14%, according to a new report from Straits Research. The analysis said the growth reflects increasing consumer interest in minimally invasive cosmetic procedures f
- Study: Safety Signals Emerge for IL-23 and IL-12/23 Inhibitors in Psoriasis Treatmenthttps://practicaldermatology.com/news/safety-signals-emerge-for-il-23-and-il-1223-inhibitors-in-psoriasis-treatment/2470971/A new analysis of psoriasis patients indicates an emergence of new safety signals associated with interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab. Researchers on the study analyzed 41.4 million adverse event (AE) reports from the FDA Adverse Event Reporting System
- Gene Expression Patterns Linked to Psoriasis Severity and Treatment Responsehttps://practicaldermatology.com/news/gene-expression-patterns-linked-to-psoriasis-severity-and-treatment-response/2470916/Gene expression abnormalities not only reflect the severity of psoriatic lesions but also predict treatment response, according to a recent study published in JID Innovations. Researchers on the study analyzed gene expression profiles in psoriatic skin using Gene Set Variation Ana